LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Uranium had no large scale application in the late 19th century and therefore no large uranium mines existed. In the beginning, the silver mines in Jáchymov, Austria-Hungary (now Czech Republic) were the only large sources for uranium ore. The uranium ore was only a byproduct of the mining activities. In the first extraction of radium, Curie used the residues after extraction of uranium from pitchblende. The uranium had been extracted by dissolution in sulfuric acid leaving radium sulfate, which is similar to barium sulfate but even less soluble in the residues. The residues also contained rather substantial amounts of barium sulfate which thus acted as a carrier for the radium sulfate. The first steps of the radium extraction process involved boiling with sodium hydroxide, followed by hydrochloric acid treatment to minimize impurities of other compounds. The remaining residue was then treated with sodium carbonate to convert the barium sulfate into barium carbonate (carrying the radium), thus making it soluble in hydrochloric acid. After dissolution, the barium and radium were reprecipitated as sulfates; this was then repeated to further purify the mixed sulfate. Some impurities that form insoluble sulfides were removed by treating the chloride solution with hydrogen sulfide, followed by filtering.
== Definition == Stimulant is an overarching term that covers many drugs including those that increase the activity of the central nervous system and the body, drugs that are pleasurable and invigorating, or drugs that have sympathomimetic effects. Sympathomimetic effects are those effects that mimic or copy the actions of the sympathetic nervous system. The sympathetic nervous system is a part of the nervous system that prepares the body for action, such as increasing the heart rate, blood pressure, and breathing rate. Stimulants can activate the same receptors as the natural chemicals released by the sympathetic nervous system (namely epinephrine and norepinephrine) and cause similar effects. Psychostimulant refers to a subset of substances within the stimulant drug class that act at the dopamine transporter (DAT), a protein that normally clears dopamine from the synaptic cleft. Amphetamine, methylphenidate, cocaine, and modafinil are examples of psychostimulants that promote arousal and affect task performance in a dose-dependent manner. Psychostimulants act at DAT by inhibiting dopamine reuptake or by initiating transporter-mediated dopamine efflux (i.e., reverse transport), thereby producing indirect dopamine agonist effects in the central nervous system. The DAT-mediated actions of psychostimulants contrast with other central nervous system stimulants that can overlap in behavioural effects, such as caffeine, a drug that promotes wakefulness primarily through antagonism of adenosine receptors.
Solomon campaigned for subsidised medical services, directly influencing the Labour concept of the welfare state and the creation of the British National Health Service in 1948 Muriel Spark, novelist (Jewish father, possible Jewish mother; converted to Catholicism later in life) Bob Stanley (born Robert Andrew Shukman; 25 December 1964); musician, journalist, author, film producer; member of indie pop group Saint Etienne and music journalist for NME, Melody Maker, Mojo, The Guardian and The Times, as well as writing three books on music and football; also has a career as a DJ and as a producer of record labels, and has collaborated on a series of films about London. His second publication, Yeah! Yeah! Yeah!: The Story of Modern Pop, published by Faber & Faber; third publication Let's Do It: The Birth of Pop Music: A History, published by Pegasus. George Steiner, FBA (April 23, 1929 – February 3, 2020) author, literary critic, essayist, philosopher, novelist and educator; wrote about relationship between language, literature and society, as well as impact of the Holocaust; ranked "among the great minds in today's literary world"; was Professor University of Geneva (1974–94), Professor of Comparative Literature and Fellow in the University of Oxford (1994–95), Professor of Poetry in Harvard University (2001–02) and Fellow of Churchill College, Cambridge.
Sources: en.wikipedia.org
Prozac had sales in excess of $1 billion per year in the late 1990s. Barr Laboratories of the U.S. obtained exclusivity for all of the approved dosage forms (10 mg, 20 mg) except one (40 mg), which was obtained by Reddy's. Lilly had numerous other patents surrounding the drug compound and had already enjoyed a long period of patent protection. The case to allow generic sales was heard twice by the Federal Circuit Court, and Reddy's won both hearings. Reddy's generated nearly $70 million in revenue during the initial six-month exclusivity period. With such high returns at stake, Reddy's was gambling on the success of the litigation; failure to win the case could have cost them millions of dollars, depending on the length of the trial. The fluoxetine marketing success was followed by the American launch of Reddy's house-branded ibuprofen tablets in 400, 600 and 800 mg strengths, in January 2003. Direct marketing under the Reddy's brand name represented a significant step in the company's efforts to build a strong and sustainable US generic business. It was the first step in building Reddy's fully-fledged distribution network in the US market. In 2015, Dr. Reddy's Laboratories bought the established brands of Belgian drugmaker UCB SA in South Asia for ₹8 billion ($128.38 million). Dr. Reddy's Laboratories also signed a licensing pact with XenoPort for their experimental treatment to treat plaque psoriasis. As per the agreement, Dr. Reddy's will be granted exclusive US rights to develop and commercialise XP23829 for all indications for an upfront payment of $47.5 million.
Birch wood is a type of wood of the birch. Birch wood is pale yellow-brown wood having a close, straight grain and uniform texture that finishes to a smooth surface. Sometimes it is dyed to imitate mahogany. This type of wood is used for among others firewood, turnery, furniture, cabinetry, tool handles, hoops, plywood, flooring and shoe heels.
Dehydrogenase enzymes transfer electrons from the substrate to an electron carrier; what carrier is used depends on the reaction taking place. Common electron acceptors used by this subclass are NAD+, FAD, and NADP+. Electron carriers are reduced in this process and considered oxidizers of the substrate. Electron carriers are coenzymes that are often referred to as "redox cofactors."
=== Others === HiBiT-tag was developed by Scientists at Promega. It is an 11-amino-acid peptide tag, and it can be fused to the N- or C-terminus or internal locations of proteins. Its small size leads to a rapid knock-in of this tag with other proteins through CRISPR/Cas9 technology.
Sources: en.wikipedia.org
(death announced on this date) 25 October – Tommy Callaghan, 78, Scottish football player (Dunfermline Athletic, Celtic, Clydebank) and manager. 2 November – Janey Godley, 63, Scottish stand-up comedian and writer. 10 November – Derrick Grant, 86, Scottish rugby union player (Hawick, national team). 22 November – Kenny Aird, 77, Scottish footballer (St Mirren, St Johnstone, Heart of Midlothian). 28 November – John McNamee, 83, Scottish footballer (Newcastle United, Hibernian, Blackburn Rovers). (death announced on this date) 4 December – John Docherty, 84, Scottish football player (Brentford) and manager (Millwall, Cambridge United). (death announced on this date) 11 December – Alex Edwards, 78, Scottish footballer (Dunfermline Athletic, Hibernian). 28 December – Charlie Wright, 86, Scottish football player (Grimsby Town, Charlton Athletic) and manager (Bolton Wanderers)
The consequence of a broken ligament can be instability of the joint. Not all broken ligaments need surgery, but, if surgery is needed to stabilise the joint, the broken ligament can be repaired. Scar tissue may prevent this. If it is not possible to fix the broken ligament, other procedures such as the Brunelli procedure can correct the instability. Instability of a joint can over time lead to wear of the cartilage and eventually to osteoarthritis.
2-Amino-1-methyl-1H-imidazol-4-ol (or 2-amino-1-methylimidazol-4-ol) 2-Amino-1-methyl-4,5-dihydro-1H-imidazol-4-one 2-Imino-1-methyl-2,3-dihydro-1H-imidazol-4-ol (or 2-imino-1-methyl-3H-imidazol-4-ol) 2-Imino-1-methylimidazolidin-4-one 2-Imino-1-methyl-2,5-dihydro-1H-imidazol-4-ol (or 2-imino-1-methyl-5H-imidazol-4-ol) Creatinine starts to decompose at around 300 °C.
Continuing Arab disquiet over Allied intentions also led during 1918 to the British Declaration to the Seven and the Anglo-French Declaration, the latter promising "the complete and final liberation of the peoples who have for so long been oppressed by the Turks, and the setting up of national governments and administrations deriving their authority from the free exercise of the initiative and choice of the indigenous populations". In 1919, King Hussein refused to ratify the Treaty of Versailles. After February 1920, the British ceased to pay subsidy to him. In August 1920, five days after the signing of the Treaty of Sèvres, which formally recognized the Kingdom of Hejaz, Curzon asked Cairo to procure Hussein's signature to both treaties and agreed to make a payment of £30,000 conditional on signature. Hussein declined and in 1921, stated that he could not be expected to "affix his name to a document assigning Palestine to the Zionists and Syria to foreigners." Following the 1921 Cairo Conference, Lawrence was sent to try and obtain the King's signature to a treaty as well as to Versailles and Sèvres, a £60,000 annual subsidy being proposed; this attempt also failed. During 1923, the British made one further attempt to settle outstanding issues with Hussein and once again, the attempt foundered, Hussein continued in his refusal to recognize the Balfour Declaration or any of the Mandates that he perceived as being his domain.
Paracetamol, or acetaminophen, is an analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely available over-the-counter drug sold generically or under various brand names, including Tylenol and Panadol. Paracetamol relieves pain in acute mild migraine and episodic tension headaches. At a standard dose, paracetamol slightly reduces fever, though it is inferior to ibuprofen in that respect: the benefits of its use for fever are unclear, particularly in the context of fever of viral origins. Paracetamol is effective for pain after wisdom tooth extraction, but it is less effective than ibuprofen. The combination of paracetamol and ibuprofen provides greater analgesic efficacy than either drug alone. The pain relief paracetamol provides in osteoarthritis is small and clinically insignificant. Evidence supporting its use in low back pain, cancer pain, and neuropathic pain is insufficient. Paracetamol is the first-line treatment for pain and fever in pregnancy; no causal association with neurodevelopmental disorders has been established, while untreated pain and fever can harm the mother and fetus. At a recommended maximum daily dose for an adult of three to four grams, paracetamol is safe and effective in the short term when used as directed, with uncommon adverse effects similar to those of ibuprofen. It is often used in patients who cannot tolerate nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.